Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-nectin-4 antibody-drug conjugate ADRX-0706

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4) that is conjugated to the tubulin inhibitor and cytotoxic agent AP052, with potential antineoplastic activity. Upon administration of the anti-nectin-4 ADC ADRX-0706, the anti-nectin-4 antibody targets and binds to nectin-4 expressed on tumor cells. Upon binding and internalization, AP052 targets and binds to tubulin, and inhibits its polymerization. This results in G2/M phase arrest and induces apoptosis in nectin-4-expressing tumor cells. Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, but has a restricted distribution in normal tissue. It is associated with poor disease prognosis. ADRX-0706 has a drug-antibody ratio (DAR) of eight.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC ADRX-0706
anti-nectin-4 ADC ADRX-0706
anti-nectin-4/AP052 antibody-drug conjugate ADRX-0706
Code name:ADRX 0706
ADRX-0706
ADRX0706
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search